Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Watson Pharmaceuticals, Inc. (WPI) continues to expand and strengthen its footprint in ex-US territories. The company recently inked a deal with Brazilian company, Moksha8, for the manufacture and supply of certain products.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Terms of the Deal
Under the terms of the deal, Watson Pharma will provide Moksha8 with specific products that will be marketed, sold, and distributed exclusively by the latter in Brazil and Mexico. The companies will initially start with a dozen products which may be expanded later.
Watson Pharma's initial investment of about $30 million in Moksha8 will provide it with a significant minority position in Moksha8. Watson Pharma could increase its equity position further by investing another $20 million. However, the additional investment depends on Moksha8's ability to acquire third-party products in the coming year. Besides Watson Pharma, Moksha8 has partnership agreements with several other companies including Roche (RHHBY), Pfizer (PFE) and BioCryst (BCRX).
Deal Strengthens Presence in Latin America
With a 75% share of the $40 billion Latin American market, Brazil and Mexico are the two largest markets in this region. Moksha8 already has a presence in Latin America with about 180 sales reps marketing 21 branded products that focus on central nervous system disorders, infectious disease and pain.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
This deal should allow Watson Pharma to strengthen its presence in Latin America, especially Mexico. The company already has a presence in the Brazilian generics market through a subsidiary.
Neutral on Watson Pharma
We currently have a Neutral recommendation on Watson Pharma, which is supported by a Zacks #3 Rank (short-term “Hold” rating). We believe that Watson Pharma's cost-saving initiative and new product launches, both branded and generic, will help drive growth. We also view the company's acquisition of Arrow as a smart strategic move. This acquisition has helped Watson Pharma expand its footprint in ex-US territories, especially in countries like Australia, New Zealand, Brazil, Scandinavia, Germany, Central and Eastern Europe, Turkey, Japan and South Africa. It has also boosted Watson Pharma's product offerings and pipeline. However, we remain concerned about integration risks and fierce competition in both the branded and generic markets.
WATSON PHARMA (WPI): Free Stock Analysis Report
Zacks Investment Research
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.